ALK and non-small cell lung carcinoma: This NMA aimed to compare the efficacy, safety, and effects on quality of life of different anaplastic lymphoma kinase (ALK)-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).